Treatment of Small Cell Lung Cancer

Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

      Background

      Small cell lung cancer (SCLC) is a lethal disease for which there have been only small advances in diagnosis and treatment in the past decade. Our goal was to revise the evidence-based guidelines on staging and best available treatment options.

      Methods

      A comprehensive literature search covering 2004 to 2011 was conducted in MEDLINE, Embase, and five Cochrane databases using SCLC terms. This was cross-checked with the authors' own literature searches and knowledge of the literature. Results were limited to research in humans and articles written in English.

      Results

      The staging classification should include both the old Veterans Administration staging classification of limited stage (LS) and extensive stage (ES), as well as the new seventh edition American Joint Committee on Cancer/International Union Against Cancer staging by TNM. The use of PET scanning is likely to improve the accuracy of staging. Surgery is indicated for carefully selected stage I SCLC. LS disease should be treated with concurrent chemoradiotherapy in patients with good performance status. Thoracic radiotherapy should be administered early in the course of treatment, preferably beginning with cycle 1 or 2 of chemotherapy. Chemotherapy should consist of four cycles of a platinum agent and etoposide. ES disease should be treated primarily with chemotherapy consisting of a platinum agent plus etoposide or irinotecan. Prophylactic cranial irradiation prolongs survival in those individuals with both LS and ES disease who achieve a complete or partial response to initial therapy. To date, no molecularly targeted therapy agent has demonstrated proven efficacy against SCLC.

      Conclusion

      Evidence-based guidelines are provided for the staging and treatment of SCLC. LS-SCLC is treated with curative intent with 20% to 25% 5-year survival. ES-SCLC is initially responsive to standard treatment, but almost always relapses, with virtually no patients surviving for 5 years. Targeted therapies have no proven efficacy against SCLC.
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lewis SZ
        • Diekemper R
        • Addrizzo-Harris DJ
        Methodology for development of guidelines for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2013; 143: 41S-50S
        • Howlander N
        • Noone AM
        • Krapcho M
        • et al.
        SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Bethesda, MD2011
        • Cuffe S
        • Moua T
        • Summerfield R
        • Roberts H
        • Jett J
        • Shepherd FA
        Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers.
        J Thorac Oncol. 2011; 6: 818-822
        • Haynes RB
        • McKibbon KA
        • Wilczynski NL
        • Walter SD
        • Werre SR
        • Hedges Team
        Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey.
        BMJ. 2005; 330: 1179
        • Zelen M
        Keynote address on biostatistics and data retrieval.
        Cancer Chemother Rep 3. 1973; 4: 31-42
        • Stahel RA
        • Ginsberg
        • et al.
        Staging and prognostic factors in small cell lung cancer: a consensus report.
        Lung Cancer. 1989; 5: 119-126
        • Micke P
        • Faldum A
        • Metz T
        • et al.
        Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?.
        Lung Cancer. 2002; 37: 271-276
        • Goldstraw P
        • Crowley J
        • Chanksy K
        • et al.
        The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors.
        J Thorac Oncol. 2007; 2: 706-714
        • Shepherd FA
        • Crowley J
        • Van Houtte P
        • International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions
        • et al.
        The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer.
        J Thorac Oncol. 2007; 2: 1067-1077
        • Vallières E
        • Shepherd FA
        • Crowley J
        • International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions
        • et al.
        The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.
        J Thorac Oncol. 2009; 4: 1049-1059
        • Ignatius Ou SH
        • Zell JA
        The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition.
        J Thorac Oncol. 2009; 4: 300-310
        • Hochstenbag MMH
        • Twijnstra A
        • Wilmink JT
        • Wouters EF
        • ten Velde GP
        Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis.
        J Neurooncol. 2000; 48: 243-248
        • Seute T
        • Leffers P
        • Wilmink JT
        • ten Velde GP
        • Twijnstra A
        Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy.
        J Clin Oncol. 2006; 24: 2079-2083
        • Campling B
        • Quirt I
        • DeBoer G
        • Feld R
        • Shepherd FA
        • Evans WK
        Is bone marrow examination in small-cell lung cancer really necessary?.
        Ann Intern Med. 1986; 105: 508-512
        • Tritz DB
        • Doll DC
        • Ringenberg QS
        • et al.
        Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables.
        Cancer. 1989; 63: 763-766
        • Levitan N
        • Byrne RE
        • Bromer RH
        • et al.
        The value of the bone scan and bone marrow biopsy staging small cell lung cancer.
        Cancer. 1985; 56: 652-654
        • Brink I
        • Schumacher T
        • Mix M
        • et al.
        Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer.
        Eur J Nucl Med Mol Imaging. 2004; 31: 1614-1620
        • Bradley JD
        • Dehdashti F
        • Mintun MA
        • Govindan R
        • Trinkaus K
        • Siegel BA
        Positron emission tomography in limited-stage small-cell lung cancer: a prospective study.
        J Clin Oncol. 2004; 22: 3248-3254
        • Chin Jr, R
        • McCain TW
        • Miller AA
        • et al.
        Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study.
        Lung Cancer. 2002; 37: 1-6
        • Kut V
        • Spies W
        • Spies S
        • Gooding W
        • Argiris A
        Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET).
        Am J Clin Oncol. 2007; 30: 45-50
        • Fischer BM
        • Mortensen J
        • Langer SW
        • et al.
        A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis.
        Ann Oncol. 2007; 18: 338-345
        • Vinjamuri M
        • Craig M
        • Campbell-Fontaine A
        • Almubarak M
        • Gupta N
        • Rogers JS
        Can positron emission tomography be used as a staging tool for small-cell lung cancer?.
        Clin Lung Cancer. 2008; 9: 30-34
        • Azad A
        • Chionh F
        • Scott AM
        • et al.
        High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer.
        Mol Imaging Biol. 2010; 12: 443-451
        • Schumacher T
        • Brink I
        • Mix M
        • et al.
        FDG-PET imaging for the staging and follow-up of small cell lung cancer.
        Eur J Nucl Med. 2001; 28: 483-488
        • Shen YY
        • Shiau YC
        • Wang JJ
        • Ho ST
        • Kao CH
        Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer.
        Anticancer Res. 2002; 22: 1257-1264
        • Blum R
        • MacManus MP
        • Rischin D
        • Michael M
        • Ball D
        • Hicks RJ
        Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience.
        Am J Clin Oncol. 2004; 27: 164-171
        • Hauber HP
        • Bohuslavizki KH
        • Lund CH
        • Fritscher-Ravens A
        • Meyer A
        • Pforte A
        Positron emission tomography in the staging of small-cell lung cancer : a preliminary study.
        Chest. 2001; 119: 950-954
        • Niho S
        • Fujii H
        • Murakami K
        • et al.
        Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer.
        Lung Cancer. 2007; 57: 328-333
        • Kamel EM
        • Zwahlen D
        • Wyss MT
        • Stumpe KD
        • von Schulthess GK
        • Steinert HC
        Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
        J Nucl Med. 2003; 44: 1911-1917
        • van Loon J
        • De Ruysscher D
        • Wanders R
        • et al.
        Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study.
        Int J Radiat Oncol Biol Phys. 2010; 77: 329-336
        • van Loon J
        • Offermann C
        • Bosmans G
        • et al.
        18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study.
        Radiother Oncol. 2008; 87: 49-54
        • Fischer BM
        • Mortensen J
        • Langer SW
        • et al.
        PET/CT imaging in response evaluation of patients with small cell lung cancer.
        Lung Cancer. 2006; 54: 41-49
        • Shields AF
        • Mankoff DA
        • Link JM
        • et al.
        Carbon-11-thymidine and FDG to measure therapy response.
        J Nucl Med. 1998; 39: 1757-1762
        • Yamamoto Y
        • Kameyama R
        • Murota M
        • Bandoh S
        • Ishii T
        • Nishiyama Y
        Early assessment of therapeutic response using FDG PET in small cell lung cancer.
        Mol Imaging Biol. 2009; 11: 467-472
        • Lee YJ
        • Cho A
        • Cho BC
        • et al.
        High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer.
        Clin Cancer Res. 2009; 15: 2426-2432
        • Onitilo AA
        • Engel JM
        • Demos JM
        • Mukesh B
        Prognostic significance of 18 F-fluorodeoxyglucose – positron emission tomography after treatment in patients with limited stage small cell lung cancer.
        Clin Med Res. 2008; 6: 72-77
        • Pandit N
        • Gonen M
        • Krug L
        • Larson SM
        Prognostic value of [18F]FDG-PET imaging in small cell lung cancer.
        Eur J Nucl Med Mol Imaging. 2003; 30: 78-84
        • Fox W
        • Scadding JG
        Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up.
        Lancet. 1973; 2: 63-65
        • Pignon JP
        • Arriagada R
        • Ihde DC
        • et al.
        A meta-analysis of thoracic radiotherapy for small-cell lung cancer.
        N Engl J Med. 1992; 327: 1618-1624
        • Warde P
        • Payne D
        Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis.
        J Clin Oncol. 1992; 10: 890-895
        • Simon GR
        • Turrisi A
        Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).
        Chest. 2007; 132: 324S-339S
        • Friess GG
        • McCracken JD
        • Troxell ML
        • Pazdur R
        • Coltman Jr, CA
        • Eyre HJ
        Effect of initial resection of small-cell carcinoma of the lung: a review of Southwest Oncology Group Study 7628.
        J Clin Oncol. 1985; 3: 964-968
        • Karrer K
        • Shields TW
        • Denck H
        • Hrabar B
        • Vogt-Moykopf I
        • Salzer GM
        The importance of surgical and multimodality treatment for small cell bronchial carcinoma.
        J Thorac Cardiovasc Surg. 1989; 97: 168-176
        • Lucchi M
        • Mussi A
        • Chella A
        • et al.
        Surgery in the management of small cell lung cancer.
        Eur J Cardiothorac Surg. 1997; 12: 689-693
        • Maassen W
        • Greschuchna D
        Small cell carcinoma of the lung—to operate or not? Surgical experience and results.
        Thorac Cardiovasc Surg. 1986; 34: 71-76
        • Merkle NM
        • Mickisch GH
        • Kayser K
        • Drings P
        • Vogt-Moykopf I
        Surgical resection and adjuvant chemotherapy for small cell carcinoma.
        Thorac Cardiovasc Surg. 1986; 34: 39-42
        • Miyazawa N
        • Tsuchiya R
        • Naruke T
        • et al.
        A clinico-pathological study of surgical treatment for small cell carcinoma of the lung.
        Jpn J Clin Oncol. 1986; 16: 297-307
        • Osterlind K
        • Hansen M
        • Hansen HH
        • Dombernowsky P
        Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer. A study of 150 operable patients.
        Eur J Cancer Clin Oncol. 1986; 22: 589-593
        • Schreiber D
        • Rineer J
        • Weedon J
        • et al.
        Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?.
        Cancer. 2010; 116: 1350-1357
        • Shepherd FA
        • Ginsberg RJ
        • Feld R
        • Evans WK
        • Johansen E
        Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience.
        J Thorac Cardiovasc Surg. 1991; 101: 385-393
        • Yu JB
        • Decker RH
        • Detterbeck FC
        • Wilson LD
        Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer.
        J Thorac Oncol. 2010; 5: 215-219
        • Inoue M
        • Nakagawa K
        • Fujiwara K
        • Fukuhara K
        • Yasumitsu T
        Results of preoperative mediastinoscopy for small cell lung cancer.
        Ann Thorac Surg. 2000; 70: 1620-1623
        • Simoff MJ
        • Lally B
        • Slade MG
        Symptom management in patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2013; 143: e455S-e497S
        • Wolf J
        • Patno ME
        • Roswit B
        • D'Esopo N
        Controlled study of survival of patients with clinically inoperable lung cancer treated with radiation therapy.
        Am J Med. 1966; 40: 360-367
        • Fried DB
        • Morris DE
        • Poole C
        • et al.
        Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.
        J Clin Oncol. 2004; 22: 4837-4845
        • De Ruysscher D
        • Pijls-Johannesma M
        • Bentzen SM
        • et al.
        Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer.
        J Clin Oncol. 2006; 24: 1057-1063
        • Turrisi III, AT
        • Kim K
        • Blum R
        • et al.
        Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
        N Engl J Med. 1999; 340: 265-271
        • Schild SE
        • Bonner JA
        • Shanahan TG
        • et al.
        Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
        Int J Radiat Oncol Biol Phys. 2004; 59: 943-951
        • Fu KK
        • Pajak TF
        • Trotti A
        • et al.
        A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
        Int J Radiat Oncol Biol Phys. 2000; 48: 7-16
        • Le Pechoux C
        • Mauguen A
        • Schild SE
        • et al.
        Accelerated or hyperfractionated radiotherapy (RT) versus conventional RT in non metastatic lung cancer (LC): individual patient data (IPD) meta-analysis from 2279 patients.
        J Thorac Oncol. 2010; 5: S73
        • Schild SE
        • Bonner JA
        • Hillman S
        • et al.
        Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
        J Clin Oncol. 2007; 25: 3124-3129
        • Jeremic B
        • Shibamoto Y
        • Nikolic N
        • et al.
        Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.
        J Clin Oncol. 1999; 17: 2092-2099
        • Gregor A
        Prophylactic cranial irradiation in small-cell lung cancer: is it ever indicated?.
        Oncology (Williston Park). 1998; 12: 19-24
        • Johnson BE
        • Becker B
        • Goff II, WB
        • et al.
        Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer.
        J Clin Oncol. 1985; 3: 1659-1667
        • Catane R
        • Schwade JG
        • Yarr I
        • et al.
        Follow-up neurological evaluation in patients with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapy.
        Int J Radiat Oncol Biol Phys. 1981; 7: 105-109
        • Frytak S
        • Shaw JN
        • O'Neill BP
        • et al.
        Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation.
        Am J Clin Oncol. 1989; 12: 27-33
        • Aupérin A
        • Arriagada R
        • Pignon JP
        • et al.
        • Prophylactic Cranial Irradiation Overview Collaborative Group
        Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission.
        N Engl J Med. 1999; 341: 476-484
        • Patel S
        • Macdonald OK
        • Suntharalingam M
        Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer.
        Cancer. 2009; 115: 842-850
        • Slotman B
        • Faivre-Finn C
        • Kramer G
        • EORTC Radiation Oncology Group and Lung Cancer Group
        • et al.
        Prophylactic cranial irradiation in extensive small-cell lung cancer.
        N Engl J Med. 2007; 357: 664-672
        • Slotman BJ
        • Mauer ME
        • Bottomley A
        • et al.
        Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups.
        J Clin Oncol. 2009; 27: 78-84
        • Le Péchoux C
        • Dunant A
        • Senan S
        • et al.
        • Prophylactic Cranial Irradiation (PCI) Collaborative Group
        Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.
        Lancet Oncol. 2009; 10: 467-474
        • Baka S
        • Califano R
        • Ferraldeschi R
        • et al.
        Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer.
        Br J Cancer. 2008; 99: 442-447
        • de Jong WK
        • Groen HJM
        • Koolen MGJ
        • et al.
        Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer.
        Eur J Cancer. 2007; 43: 2345-2350
        • Amarasena IU
        • Walters JAE
        • Wood-Baker R
        • Fong K
        Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.
        Cochrane Database Syst Rev. 2008; (CD006849.)
        • Noda K
        • Nishiwaki Y
        • Kawahara M
        • et al.
        Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
        N Engl J Med. 2002; 346: 85-91
        • Eckardt JR
        • von Pawel J
        • Papai Z
        • et al.
        Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
        J Clin Oncol. 2006; 24: 2044-2051
        • Lara Jr, PN
        • Chansky K
        • Shibata T
        • et al.
        Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.
        Cancer. 2010; 116: 5710-5715
        • Zatloukal P
        • Cardenal F
        • Szczesna A
        • et al.
        A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
        Ann Oncol. 2010; 21: 1810-1816
        • Hanna N
        • Bunn Jr, PA
        • Langer C
        • et al.
        Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
        J Clin Oncol. 2006; 24: 2038-2043
        • Schmittel A
        • Sebastian M
        • Fischer von Weikersthal L
        • Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group
        • et al.
        A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
        Ann Oncol. 2011; 22: 1798-1804
        • Hermes A
        • Bergman B
        • Bremnes R
        • et al.
        Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
        J Clin Oncol. 2008; 26: 4261-4267
        • Lara Jr, PN
        • Natale R
        • Crowley J
        • et al.
        Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
        J Clin Oncol. 2009; 27: 2530-2535
        • Lima JPSN
        • dos Santos LV
        • Sasse EC
        • Lima CS
        • Sasse AD
        Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis.
        J Thorac Oncol. 2010; 5: 1986-1993
        • Kalemkerian GP
        • Akerley W
        • Bogner P
        • National Comprehensive Cancer Network
        • et al.
        Small cell lung cancer.
        J Natl Compr Canc Netw. 2011; 9: 1086-1113
        • Dimitroulis J
        • Rapti A
        • Stathopoulos GP
        • et al.
        Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a phase III study.
        Oncol Rep. 2008; 20: 879-884
        • Niell HB
        • Herndon II, JE
        • Miller AA
        • Cancer and Leukemia Group
        • et al.
        Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
        J Clin Oncol. 2005; 23: 3752-3759
        • Socinski MA
        • Weissman C
        • Hart LL
        • et al.
        Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
        J Clin Oncol. 2006; 24: 4840-4847
        • Socinski MA
        • Smit EF
        • Lorigan P
        • et al.
        Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
        J Clin Oncol. 2009; 27: 4787-4792
        • Lee SM
        • Woll PJ
        • Rudd R
        • et al.
        Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
        J Natl Cancer Inst. 2009; 101: 1049-1057
        • Pujol JL
        • Breton JL
        • Gervais R
        • et al.
        Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.
        J Clin Oncol. 2007; 25: 3945-3951
        • Horn L
        • Dahlberg SE
        • Sandler AB
        • et al.
        Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
        J Clin Oncol. 2009; 27: 6006-6011
        • Ready NE
        • Dudek AZ
        • Pang HH
        • et al.
        Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
        J Clin Oncol. 2011; 29: 4436-4441
        • Spigel DR
        • Greco FA
        • Zubkus JD
        • et al.
        Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
        J Thorac Oncol. 2009; 4: 1555-1560
        • O'Bryan RM
        • Crowley JJ
        • Kim PN
        • et al.
        Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study.
        Cancer. 1990; 65: 856-860
        • Postmus PE
        • Smit EF
        • Kirkpatrick A
        • Splinter TA
        Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group.
        Eur J Cancer. 1993; 29A: 204-207
        • Sculier JP
        • Lafitte JJ
        • Lecomte J
        • European Lung Cancer Working Party
        • et al.
        A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer.
        Ann Oncol. 2002; 13: 1454-1459
        • Spiro SG
        • Souhami RL
        • Geddes DM
        • et al.
        Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.
        Br J Cancer. 1989; 59: 578-583
        • Wolff SN
        • Birch R
        • Sarma P
        • Greco FA
        Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial.
        Cancer Treat Rep. 1986; 70: 583-587
        • O'Brien MER
        • Ciuleanu TE
        • Tsekov H
        • et al.
        Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
        J Clin Oncol. 2006; 24: 5441-5447
        • von Pawel J
        • Schiller JH
        • Shepherd FA
        • et al.
        Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
        J Clin Oncol. 1999; 17: 658-667
        • von Pawel J
        • Gatzemeier U
        • Pujol JL
        • et al.
        Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.
        J Clin Oncol. 2001; 19: 1743-1749
        • Eckardt JR
        • von Pawel J
        • Pujol JL
        • et al.
        Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
        J Clin Oncol. 2007; 25: 2086-2092
        • Inoue A
        • Sugawara S
        • Yamazaki K
        • et al.
        Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
        J Clin Oncol. 2008; 26: 5401-5406
        • Jotte R
        • Conkling P
        • Reynolds C
        • et al.
        Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
        J Clin Oncol. 2011; 29: 287-293
        • Jotte R
        • Von Pawel J
        • Spigel DR
        • et al.
        Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).
        J Clin Oncol. 2011; 29: 453s
        • Giaccone G
        • Ferrati P
        • Donadio M
        • Testore F
        • Calciati A
        Reinduction chemotherapy in small cell lung cancer.
        Eur J Cancer Clin Oncol. 1987; 23: 1697-1699
        • Postmus PE
        • Berendsen HH
        • van Zandwijk N
        • Splinter TA
        • Burghouts JT
        • Bakker W
        Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy.
        Eur J Cancer Clin Oncol. 1987; 23: 1409-1411
        • Owonikoko TK
        • Ragin CC
        • Belani CP
        • et al.
        Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.
        J Clin Oncol. 2007; 25: 5570-5577
        • Ardizzoni A
        • Favaretto A
        • Boni L
        • et al.
        Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis—a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study.
        J Clin Oncol. 2005; 23: 569-575
        • Okamoto H
        • Watanabe K
        • Kunikane H
        • et al.
        Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.
        Br J Cancer. 2007; 97: 162-169
        • Souhami RL
        • Spiro SG
        • Rudd RM
        • et al.
        Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
        J Natl Cancer Inst. 1997; 89: 577-580
        • Yuen AR
        • Zou GY
        • Turrisi AT
        • et al.
        Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma.
        Cancer. 2000; 89: 1953-1960
        • Schild SE
        • Stella PJ
        • Brooks BJ
        • et al.
        Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly.
        Cancer. 2005; 103: 2349-2354
        • Siu LL
        • Shepherd FA
        • Murray N
        • Feld R
        • Pater J
        • Zee B
        Influence of age on the treatment of limited-stage small-cell lung cancer.
        J Clin Oncol. 1996; 14: 821-828
        • Quon H
        • Shepherd FA
        • Payne DG
        • et al.
        The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer.
        Int J Radiat Oncol Biol Phys. 1999; 43: 39-45